𝔖 Bobbio Scriptorium
✦   LIBER   ✦

In vitro blockade of receptor activator of nuclear factor-κB ligand prevents osteoclastogenesis induced by neuroblastoma cells

✍ Scribed by Donatella Granchi; Ilaria Amato; Luca Battistelli; Sofia Avnet; Sergio Capaccioli; Laura Papucci; Martino Donnini; Andrea Pellacani; Maria Luisa Brandi; Armando Giunti; Nicola Baldini

Publisher
John Wiley and Sons
Year
2004
Tongue
French
Weight
550 KB
Volume
111
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

Proliferation and differentiation of osteoclasts are regulated by a cytokine system that includes RANKL, which binds 2 receptors: RANK, which activates osteoclast differentiation, and osteoprotegerin (OPG), a decoy receptor that limits RANKL action. We investigated the role of the OPG/RANKL/RANK network in the pathogenesis of skeletal metastasis in neuroblastoma. Four different neuroblastoma cell lines (NB100, CHP212, SH‐SY5Y, SJ‐NK‐P) showed a large amount of OPG and RANKL transcripts. Soluble RANKL was detectable in all cell lines, but poor release of OPG was observed. SH‐SY5Y showed the lowest OPG‐to‐RANKL ratio and promoted osteoclastic differentiation of FLG29.1 and peripheral mononuclear cells, inducing expression of the osteoclast markers RANK, c‐src, c‐fos, cathepsin‐K and TRAP. SJ‐N‐KP, which released both OPG and RANKL, did not show the same capability. OPG, neutralizing anti‐RANKL antibody and antisense oligonucleotides were evaluated for their ability to inhibit RANKL activity. The neutralizing antibody hampered osteoclastic differentiation by blocking both the juxtacrine and the paracrine activity of RANKL. Our findings confirm that neuroblastoma cells induce osteoclastogenesis via RANKL and suggest that the RANKL expression associated with lack of the decoy receptor OPG could be a peculiarity of some tumors that makes them able to induce metastatic osteolysis. Moreover, our results suggest that RANKL could be a relevant target in the adjuvant therapy of bone metastatic neuroblastoma as proper neutralization revokes completely osteoclastic differentiation. © 2004 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Plasma levels of receptor activator of n
Plasma levels of receptor activator of nuclear factor-κB ligand and osteoprotegerin in patients with neuroblastoma
✍ Donatella Granchi; Alberto Garaventa; Ilaria Amato; Paolo Paolucci; Nicola Baldi 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 French ⚖ 141 KB

## Abstract Earlier reports showed that the balance between receptor activator of nuclear factor‐κB ligand (RANKL) and its decoy‐receptor osteoprotegerin (OPG) plays an important role in the pathogenesis of metastatic osteolysis induced by neuroblastoma cells. In this study, we investigated whether

Effects of disease-modifying antirheumat
Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor κB, osteoprotegerin, and receptor activator of nuclear factor κB ligand
✍ Chang-Keun Lee; Eun Young Lee; Son Mi Chung; Se Hwan Mun; Bin Yoo; Hee-Bom Moon 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 649 KB

## Abstract ## Objective To demonstrate the effects of disease‐modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through their effects on receptor activator of nuclear factor κB (RANK), osteoprotegerin (OPG), and RANK ligand (RANKL). ## Methods Peripheral b

Simvastatin, 3-hydroxy-3-methylglutaryl
Simvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, suppresses osteoclastogenesis induced by receptor activator of nuclear factor-κB ligand through modulation of NF-κB pathway
✍ Kwang Seok Ahn; Gautam Sethi; Madan M. Chaturvedi; Bharat B. Aggarwal 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 631 KB

## Abstract Simvastatin, an inhibitor of 3‐hydroxy‐3‐methylglutaryl coenzyme A reductase, is a cholesterol‐lowering drug that may play a role in bone metabolism through a mechanism that is not fully understood. Recently, receptor activator of NF‐κB ligand (RANKL), a member of the TNF superfamily, h

The antirheumatic drug leflunomide inhib
The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-κB ligand–stimulated induction of nuclear factor of activated T cells c1
✍ Makoto Urushibara; Hiroshi Takayanagi; Takako Koga; Sunhwa Kim; Miho Isobe; Yasu 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 281 KB 👁 2 views

## Abstract ## Objective Suppression of bone destruction is required as part of an effective therapeutic strategy for autoimmune arthritis. Although numerous antirheumatic drugs are in clinical use, little is known about whether they inhibit bone destruction by acting on activated T cells or other

Inhibition of nuclear factor-κB activati
Inhibition of nuclear factor-κB activation induces apoptosis in cerebellar granule cells
✍ Patrizia Piccioli; Carola Porcile; Sabrina Stanzione; Michela Bisaglia; Adriana 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

## Abstract The nuclear factor (NF)‐κB family of transcription factors plays important roles in the regulation of many activities of neuronal cells, such as synaptic transmission, inflammation, neuroprotection, and neurotoxicity. In resting cells, NF‐κB activity is present both in the cytoplasm, as